A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2011
10/06/2011	US20110245236 Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds
10/06/2011	US20110245234 Crystalline forms of sodium 4--2-methoxybenzoate
10/06/2011	US20110245230 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
10/06/2011	US20110245229 Dihydropyrazolopyrimidinone derivatives
10/06/2011	US20110245228 Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof
10/06/2011	US20110245226 Piperidinyl derivatives as modulators of chemokine receptor activity
10/06/2011	US20110245225 Quinazolinamide derivatives
10/06/2011	US20110245222 Methods for Using Carboxamide, Sulfonamide and Amine Compounds
10/06/2011	US20110245221 Aryl isoxazole compounds with antitumoural activities
10/06/2011	US20110245214 Organic compounds
10/06/2011	US20110245210 Thalidomide analogs
10/06/2011	US20110245209 Pyridopyrimidine derivatives and methods of use thereof
10/06/2011	US20110245205 Aminopyrimidines as syk inhibitors
10/06/2011	US20110245203 Derivatives of 1-amino-2-cyclopropylethylboronic acid
10/06/2011	US20110245201 Treatment of cancer
10/06/2011	US20110245199 Sulfated Depolymerized Derivatives of Expolysaccharides (Eps) from Mesophilic Marine Bacteria, Method for Preparing the Same, and Uses Thereof in Tissue Regeneration
10/06/2011	US20110245196 Novel sulfated oligosaccharide derivatives
10/06/2011	US20110245185 APO-2 ligand/trail formulations
10/06/2011	US20110245180 Modified Peptide that reduces pain in peripheral neuropathy
10/06/2011	US20110245176 Novel peptides that bind to the erythropoietin receptor
10/06/2011	US20110245175 INHIBITING INTERACTION BETWEEN THE HIF-1ALPHA AND p300/CBP WITH HYDROGEN BOND SURROGATE-BASED
10/06/2011	US20110245167 NaK-ATPase-Derived Peptide SRC Inhibitors and Ouabain Antagonists and Uses Thereof
10/06/2011	US20110245159 Salts, Solvates and Pharmaceutical Compositions of Macrocyclic Ghrelin Receptor Agonists and Methods of Using the Same
10/06/2011	US20110245155 Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
10/06/2011	US20110245147 Activation of Peptide Prodrugs by HK2
10/06/2011	US20110244576 Herpes Simplex Virus Complex
10/06/2011	US20110244574 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
10/06/2011	US20110244546 Internalizing Anti-CD74 Antibodies and Methods of Use
10/06/2011	US20110244059 Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
10/06/2011	US20110244048 Multifunctional self-assembling polymeric nanosystems
10/06/2011	US20110244046 Charge Reversible Polymers
10/06/2011	US20110244043 Controlled releasing composition
10/06/2011	US20110244038 Berry preparations and extracts
10/06/2011	US20110244027 2'-Fluoro-6'-Methylene Carbocyclic Nucleosides and Methods of Treating Viral Infections
10/06/2011	US20110244025 Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
10/06/2011	US20110244024 Microrna compositions and methods for the treatment of myelogenous leukemia
10/06/2011	US20110243995 Method for Rational Mutagenesis of Alpha/Beta T-Cell Receptors and Correspondingly Mutated MDM2-Protein Specific Alpha/Beta T-Cell Receptors
10/06/2011	US20110243992 Methods of enhancing the immunogenicity of mycobacteria and compositions for the treatment of cancer, tuberculosis, and fibrosing lung diseases
10/06/2011	US20110243974 Novel tumor antigen protein sart-3 and tumor antigen peptides thereof
10/06/2011	US20110243973 Hig2 and urlc10 epitope peptide and vaccines containing the same
10/06/2011	US20110243972 Prostate stem cell antigen vaccines and uses thereof
10/06/2011	US20110243968 Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
10/06/2011	US20110243965 Antibodies against domains of laminin-332
10/06/2011	US20110243962 Therapeutic use of specific ligand in msrv associated diseases
10/06/2011	US20110243961 Methods for treating bone cancer by administering a nerve growth factor antagonist antibody
10/06/2011	US20110243955 Antibody and uses thereof
10/06/2011	US20110243947 Antibodies against csf-1r
10/06/2011	US20110243941 Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
10/06/2011	US20110243940 Bicyclic pyranone derivatives and methods of use thereof
10/06/2011	US20110243939 Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups
10/06/2011	US20110243937 Targeting pax2 for the treatment of breast cancer
10/06/2011	US20110243936 TNFalpha-NEUTRALIZING ANTIBODIES
10/06/2011	US20110243935 Compositions and Methods for Immunotherapy
10/06/2011	US20110243934 Epha3 antibodies for the treatment of multiple myeloma
10/06/2011	US20110243933 Perifosine and Capecitabine as a Combined Treatment for Cancer
10/06/2011	US20110243931 Combination therapy with type i and type ii anti-cd20 antibodies
10/06/2011	US20110243930 Compositions and methods for the treatment of immune related diseases
10/06/2011	US20110243928 Chimeric and humanised monoclonal antibodies against interleukin-13
10/06/2011	US20110243927 Methods of inhibiting tumor growth using beta 5 integrin antagonists
10/06/2011	US20110243925 Gene Expression Profiles Being Predictive for the Response of Tumors to Pharmaceutically Effective Compounds
10/06/2011	US20110243923 Organic compounds
10/06/2011	US20110243919 Compositions and Methods for Treating Collagen-Mediated Diseases
10/06/2011	US20110243912 Growth Factor Binding Constructs Materials and Methods
10/06/2011	US20110243910 mammalian rna dependent rna polymerase
10/06/2011	US20110243892 Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
10/06/2011	US20110243891 Dihydropyrazolopyrimidinone derivative
10/06/2011	US20110243890 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus
10/06/2011	US20110243887 Il-7 fusion proteins
10/06/2011	US20110243884 Biodegradable polymer - bioactive moiety conjugates
10/06/2011	US20110243854 Methods and systems for identifying modulators of longevity
10/06/2011	US20110243851 Glucose-peg conjugates for reducing glucose transport into a cell
10/06/2011	US20110243845 Somatostatin analogs with inhibitory activity to growth hormone release
10/06/2011	US20110243843 Fluorescent silica nanoparticles for detecting lymph node and the identification method of lymph node using thereof
10/06/2011	US20110243842 Mammalian receptor proteins; related reagents and methods
10/06/2011	DE102010014427A1 Combination, to treat e.g. tumors e.g. breast cancer, and psoriasis comprises substituted N-(4-hydrosulfonimidoylphenyl)-5-(trifluorometh yl)pyrimidin-2-amine compounds and antihyperproliferative, cytostatic or cytotoxic substances
10/06/2011	DE102010014426A1 Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren Using new pan-CDK inhibitors for the treatment of tumors
10/06/2011	CA2795456A1 Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
10/06/2011	CA2795447A1 Epha3 antibodies for the treatment of multiple myeloma
10/06/2011	CA2795081A1 Antibodies against csf-1r
10/06/2011	CA2794996A1 Use of novel pan-cdk inhibitors for treating tumors
10/06/2011	CA2794674A1 Frizzled-binding agents and uses thereof
10/06/2011	CA2794555A1 Improved treatment of renal cell carcinoma
10/06/2011	CA2794513A1 Perifosine and capecitabine as a combined treatment for cancer
10/06/2011	CA2794334A1 Derivatives of 1-amino-2-cyclopropylethylboronic acid
10/06/2011	CA2793974A1 Methods of treating cancer
10/05/2011	EP2371945A1 IMMUNOTHERAPEUTIC METHOD USING ALLO-CELLS WHICH CO-EXPRESS CD1d AND TARGET ANTIGEN
10/05/2011	EP2371865A2 Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
10/05/2011	EP2371854A2 Induction of tumor immunity by variants of folate binding protein
10/05/2011	EP2371849A1 Differential in tumour gene products and use of same
10/05/2011	EP2371848A1 Differential in tumour gene products and use of same
10/05/2011	EP2371827A1 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
10/05/2011	EP2371822A1 Heterobicyclic carboxamides as inhibitors for kinases
10/05/2011	EP2371816A1 Aminocyclohexenone, their preparation and use as medicament against oxidative stress
10/05/2011	EP2371392A1 Calicheamicin derivative-carrier conjugates
10/05/2011	EP2371391A1 Therapeutic use of anti-CS1 antibodies
10/05/2011	EP2371381A2 Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
10/05/2011	EP2371368A2 Compositions and methods for treatment of inflammation and hyperkeratotic lesions
10/05/2011	EP2371365A1 Compositions comprising an epothilone and production methods
10/05/2011	EP2371364A1 Topical or intravenous co-enzyme Q10 formulations for use in treating cancer
10/05/2011	EP2371363A1 Coenzyme Q10 formulations for use in the treatment of solid tumours

1 ... 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 ... 2211